Balkrishna Industries Signs Strategic Partnership with Pirelli for Premium Car Tyres in India
Balkrishna Industries Limited (BKT) has signed an agreement with Pirelli to manufacture Pirelli-branded premium passenger car tyres in India. The partnership marks BKT's planned entry into the premium passenger car tyre segment.
Under the first phase, BKT will manufacture up to 800,000 Pirelli-branded tyres by 2030. Production will take place at one of BKT's newly constructed facilities, following Pirelli's specific technology and quality requirements.
The agreement also provides an opportunity for a second phase involving a proposed 50-50 joint venture between the two companies. The venture could include a new manufacturing plant dedicated to high-value passenger car tyres under both the Pirelli and BKT brands, serving customers in India and international markets.
Balkrishna Industries' Strategic Rationale
The partnership is expected to support BKT's expansion into the premium passenger car tyre segment, broadening its business beyond its existing areas of focus.
Pirelli will contribute its expertise in premium tyre technology, while BKT will bring its manufacturing capabilities, industrial infrastructure and understanding of the Indian market.
The companies aim to capitalise on demand for premium passenger car tyres in India. According to the press release, the Indian car tyre market is expected to grow significantly, with the premium segment presenting an opportunity for both companies.
The proposed joint venture could further expand their manufacturing presence and support their long-term business plans. The final structure and implementation of the second phase remain subject to further developments.
Balkrishna Industries-Pirelli Partnership Highlights
| Particulars | Details |
|---|---|
| Companies | Balkrishna Industries Limited (BKT) and Pirelli |
| Agreement | Strategic manufacturing partnership |
| Product | Premium passenger car tyres |
| Phase 1 | Production of up to 800,000 Pirelli-branded tyres by 2030 |
| Manufacturing Location | India, at one of BKT's newly constructed facilities |
| Phase 2 | Potential 50-50 joint venture |
| Proposed Facility | New plant dedicated to high-value passenger car tyres |
| Brands | Pirelli and BKT |
| Target Markets | India and international markets |
| Strategic Objective | Expansion into the premium passenger car tyre segment |
What to Watch Next
- Further regulatory filings from Balkrishna Industries regarding the implementation of the agreement with Pirelli.
- Progress towards the production target of 800,000 tyres by 2030.
- Updates on the proposed 50-50 joint venture, including its structure and the potential construction of a dedicated manufacturing plant.
- Announcements regarding production capacity, premium car tyre launches and the partnership's contribution to BKT's business growth.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Bajaj Nivesh Reports 9.7% Revenue Growth in Q2 FY27, Net Profit Rises 9.8%
Bajaj Nivesh Limited has reported its financial results for the quarter and half year ended September 30, 2026. The company recorded revenue from operations of Rs.297.36 crore in Q2 FY27, up 9.7% year-on-year (YoY). Net profit for the quarter stood at Rs.293.27 crore, while earnings per share increased to Rs.256.61 from Rs.233.69 in the corresponding quarter last year.
Corona Remedies Receives ANVISA GMP Certification for Two Manufacturing Facilities
Corona Remedies Limited has received Good Manufacturing Practice (GMP) Compliance Certification from Brazil’s Health Regulatory Agency, ANVISA, for its Oral Solid Dosage (OSD) manufacturing facility and Hormone manufacturing facility, both located at Bhayla, Ahmedabad, Gujarat. The company disclosed the development to BSE Limited and the National Stock Exchange of India Limited on October 22, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The certification may support the company's efforts to expand its presence in international pharmaceutical markets, subject to applicable regulatory requirements.
Magellanic Cloud Subsidiary Emerges as L1 Bidder for Bank of Maharashtra Tender Worth Rs.115 Crore
Magellanic Cloud Limited has announced that its wholly owned subsidiary, Provigil Surveillance Limited, has emerged as the lowest bidder (L1) for a Bank of Maharashtra tender valued at approximately Rs.115 crore. The project involves deploying electronic surveillance systems across more than 1,550 bank sites, with the final contract award subject to the bank issuing a formal order.